NAS:MLTX (Switzerland)
Â
Class A
$
20.36
+0.43 (+2.18%)
07:09 PM EST
Business Description
MoonLake Immunotherapeutics
ISIN : KY61559X1045
Share Class Description:
MLTX: Class ATotal Employee Number:
130Description
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 3.55 | |||||
Equity-to-Asset | 0.63 | |||||
Debt-to-Equity | 0.4 | |||||
Debt-to-EBITDA | -0.41 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -15.6 | |||||
3-Year EPS without NRI Growth Rate | -27.6 | |||||
3-Year FCF Growth Rate | -16.9 | |||||
3-Year Book Growth Rate | 50.4 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 6.34 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 73.7 | |||||
9-Day RSI | 63.29 | |||||
14-Day RSI | 59.68 | |||||
3-1 Month Momentum % | -2.62 | |||||
6-1 Month Momentum % | -5.41 | |||||
12-1 Month Momentum % | -64.22 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 8.6 | |||||
Quick Ratio | 8.6 | |||||
Cash Ratio | 7.76 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.3 | |||||
Shareholder Yield % | -4 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -79.91 | |||||
ROA % | -58.15 | |||||
ROIC % | -2936.88 | |||||
3-Year ROIIC % | -3823.33 | |||||
ROC (Joel Greenblatt) % | -8264.44 | |||||
ROCE % | -61.63 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 8 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 5.78 | |||||
Price-to-Tangible-Book | 5.78 | |||||
EV-to-EBIT | -5.8 | |||||
EV-to-EBITDA | -5.88 | |||||
EV-to-Forward-Revenue | 20.86 | |||||
EV-to-FCF | -6.44 | |||||
| Price-to-Net-Current-Asset-Value | 5.87 | |||||
| Price-to-Net-Cash | 6.95 | |||||
Earnings Yield (Greenblatt) % | -17.24 | |||||
FCF Yield % | -13.18 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:MLTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
MoonLake Immunotherapeutics Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.87 | ||
| Beta | -0.0436 | ||
| 3-Year Sharpe Ratio | 0.21 | ||
| 3-Year Sortino Ratio | 0.28 | ||
| Volatility % | 112.13 | ||
| 14-Day RSI | 59.68 | ||
| 14-Day ATR ($) | 1.05036 | ||
| 20-Day SMA ($) | 19.5565 | ||
| 12-1 Month Momentum % | -64.22 | ||
| 52-Week Range ($) | 5.95 - 62.75 | ||
| Shares Outstanding (Mil) | 83.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
MoonLake Immunotherapeutics Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
MoonLake Immunotherapeutics Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 117 days | ||
| Second quarter earnings results for 2026 | 2026-08-05 | In 25 days | ||
| MoonLake Investor Day | 2026-06-22 08:00 | 19.21 (-2.14%) | ||
| General meeting for 2026 | 2026-06-04 08:00 | 18.27 (+2.58%) | ||
| First quarter earnings results for 2026 | 2026-05-10 | 17.06 (-1.78%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-13 | 17.96 (-7.90%) | ||
| Annual report for 2025 | 2026-02-25 | 18.20 (-4.76%) | ||
| Analyst meeting for 2026 | 2026-02-23 08:00 | 18.77 (+4.39%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-22 | 18.77 (+4.39%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 10.13 (+0.80%) |
Show
Entries
MoonLake Immunotherapeutics Frequently Asked Questions
What is MoonLake Immunotherapeutics(MLTX)'s stock price today?
The current price of MLTX is $20.36. The 52 week high of MLTX is $62.75 and 52 week low is $5.95.
When is next earnings date of MoonLake Immunotherapeutics(MLTX)?
The next earnings date of MoonLake Immunotherapeutics(MLTX) is 2026-08-05 Est..
Does MoonLake Immunotherapeutics(MLTX) pay dividends? If so, how much?
MoonLake Immunotherapeutics(MLTX) does not pay dividend.
Guru Commentaries on NAS:MLTX
No articles.
Press Release
Articles on MoonLake Immunotherapeutics
Insider Sell: Santos da Silva Jorge Sells 47,775 Shares of MoonLake Immunotherapeutics (MLTX)
Jul 02, 2026
Headlines
See More- 1
Jun 24, 2026
MoonLake Immunotherapeutics prices $200M public offering of Class A shares
Seeking Alpha • 12:33am
Jun 22, 2026
MoonLake Immunotherapeutics announces $150M public offering
Seeking Alpha • 3:11pm
Jun 21, 2026
MoonLake eyes FDA filing this fall on one-year results for skin treatment
Seeking Alpha • 4:55pm
- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers